Home
/ Opthea
/ Competitors

Opthea Competitors and Similar CompaniesClear all

Opthea's competitors and similar companies include Novartis, Santen, Ocular Therapeutix and Genentech.

	Opthea Opthea (formerly Circadian Technologies) is a biopharmaceutical company developing a therapy for the treatment of retinal diseases.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Santen Santen is a specialized pharmaceutical company focusing on ophthalmology.	Ocular Therapeutix Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
Founding Date	Founding Date 2012	Founding Date 1996	Founding Date 1890	Founding Date 2006	Founding Date 1976
Type	Type Public	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development therapy	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech drug development optics pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations South Yarra, AU HQ Toorak, AU	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations Osaka, JP HQ Toronto, CA Chongqing, CN Shanghai, CN Suzhou, CN Tampere, FI Vantaa, FI see more	Locations Bedford, US HQ Bedford, US Bedford, US	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more
Employees	Employees 33	Employees 75,883	Employees 3,744	Employees 16740% increase	Employees 18,077
Valuation ($)	Valuation ($) 711.2 m	Valuation ($) N/A	Valuation ($) 4.1 b	Valuation ($) 1.8 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $25k (FY, 2025)	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $52m (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods N/A	Cost of goods $6.6m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $146k (FY, 2025)	Gross profit $49.8b (FY, 2025)	Gross profit N/A	Gross profit $45.4m (FY, 2025)	Gross profit N/A
Net income	Net income ($162.8m) (FY, 2025)	Net income $14b (FY, 2025)	Net income N/A	Net income ($265.9m) (FY, 2025)	Net income N/A
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 28 (Jul, 2025)
Phase II Trials Products	Phase II Trials Products 2 (FY, 2020)	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 19 (Jul, 2025)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 41 (Jul, 2025)
Funding
Total funding raised	Total funding raised $ 67.6m	Total funding raised $ 6.5m	Total funding raised $ 74.4m	Total funding raised $ 73.3m	Total funding raised N/A